LASA

Lasa Supergenerics Share Price

 

 

Start SIP in LASA

Start SIP

Performance

  • Low
  • ₹9
  • High
  • ₹10
  • 52 Week Low
  • ₹8
  • 52 Week High
  • ₹29
  • Open Price₹10
  • Previous Close₹10
  • Volume85,674
  • 50 DMA₹10.16
  • 100 DMA₹10.76
  • 200 DMA₹13.02

Investment Returns

  • Over 1 Month -1.68%
  • Over 3 Month -8.84%
  • Over 6 Month -24.35%
  • Over 1 Year -63.47%

Smart Investing Starts Here Start SIP with Lasa Supergenerics for Steady Growth!

Invest Now

Lasa Supergenerics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 47
  • P/B Ratio
  • 0.8
  • Average True Range
  • 0.75
  • EPS
  • 0.1
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.23
  • RSI
  • 42.89
  • MFI
  • 43.83

Lasa Supergenerics Financials

Lasa Supergenerics Technicals

EMA & SMA

Current Price
₹9.38
-0.49 (-4.96%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹10.20
  • 50 Day
  • ₹10.16
  • 100 Day
  • ₹10.76
  • 200 Day
  • ₹13.02

Resistance and Support

9.5 Pivot Speed
  • R3 9.98
  • R2 9.86
  • R1 9.62
  • S1 9.26
  • S2 9.14
  • S3 8.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lasa Supergenerics has an operating revenue of Rs. 95.29 Cr. on a trailing 12-month basis. An annual revenue growth of 41% is outstanding, Pre-tax margin of -14% needs improvement, ROE of -17% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 24% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 2 which is a POOR score indicating inconsistency in earnings, a RS Rating of 12 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 73 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lasa Supergenerics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-28 Audited Results (Revised) per share(2.5%)Final Dividend
2025-02-13 Quarterly Results
2025-01-28 Others Inter-alia, to consider 1. The issue of warrants. 2. Proposal of fund raising by way of equity shares through rights issue. 3. Other business matters. per share(2.5%)Final Dividend

Lasa Supergenerics F&O

Lasa Supergenerics Shareholding Pattern

53.65%
0%
42.14%
4.21%

About Lasa Supergenerics

  • NSE Symbol
  • LASA
  • BSE Symbol
  • 540702
  • Chairman & Managing Director
  • Dr. Omkar Pravin Herlekar
  • ISIN
  • INE670X01014

Similar Stocks to Lasa Supergenerics

Lasa Supergenerics FAQs

Lasa Supergenerics share price is ₹9 As on 16 January, 2026 | 06:25

The Market Cap of Lasa Supergenerics is ₹47 Cr As on 16 January, 2026 | 06:25

The P/E ratio of Lasa Supergenerics is -1.3 As on 16 January, 2026 | 06:25

The PB ratio of Lasa Supergenerics is 0.8 As on 16 January, 2026 | 06:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23